Commercialization, Funding & Business

Funding models. Mergers and Acquisitions.

Microbiome Therapeutics Commercialization, Funding & Business Acquisitions

Commercialization is always at the forefront of the industry’s mind when developing new therapies and human microbiome therapeutics offer their own range of challenges. Regulatory framework (or lack thereof) proved by far the biggest concern amongst respondents, both in Europe (52%) and North America (44%). A significant portion of respondents also provided their own challenges to commercialization covering a broad range of issues.

Other challenges included:

Consumer awareness and market readiness
Therapeutic safety and efficacy in a preclinical and clinical setting
Investor scepticism
Scaling platform
‘The losers in the field are tainting the reputation for the rest of us’

*Excluding Not applicable (14)

Microbiome Therapeutics Commercialization, Funding & Business Acquisitions

How are novel funding models affecting your business?

*Excluding Not applicable (46)

Some estimates predict the human microbiome market will be worth US$3.2 billion by 2024, and novel funding models and business deals such as consolidations, acquisitions and partnerships are becoming increasingly prevalent. Additionally, with investment coming in from venture capital firms such as Seventure Partners, there is more and more money in the industry. Respondents saw Ferring's acquisition of Rebiotix as the biggest deal of 2018, closely followed by the collaboration between Enterome and Takeda.

However, whilst these novel funding models are gaining in size, they appear to still not be having a huge impact on the majority of companies in the industry.

53% of respondents said that novel funding models have had a neutral effect on their business, 34% said they have had a positive impact, and just 12% a negative.